MENU

News | CellFree Sciences

header jp

header en

News

The development serological markers for detecting recent Plasmodium vivax infection has been successful

Category: Press releases Created: Tuesday, 12 May 2020

The international research group comprising of Proteo-Science Center, Ehime University’s Dr. Eizo Takashima, Dr. Masayuki Morita, and Dr. Takafumi Tsuboi along with CellFree Sciences Co., Ltd.’s Dr. Matthias Harbers succeeded in developing a serological diagnostic marker that can identify those with dormant liver stage infections, which are the causes of Plasmodium v​​ivax recurrences.

 

This result has been achieved by an international joint research project with the main members including Proteo-Science Center, Ehime University, CellFree Sciences Co., Ltd., The Walter and Eliza Hall Institute of Medical Research (WEHI), Pasteur Institute, and Foundation for Innovative New Diagnostics (FIND).

Further, this project was started with assistance from the Global Health Innovative Technology Fund (GHIT Fund) between October 2015 and March 2017.

 

This research result allows the diagnosis of Plasmodium v​​ivax’s dormant liver stage parasites which has been a difficult challenge in eliminating malaria, for the first time in the world. It can be seen as an important result to safely and effectively promote the treatment.

 

The paper regarding this research result has been published on the May 12th (Tues.) 2020 issue of the Nature Medicine.

Development and validation of serological markers for detecting recent Plasmodium vivax infection

 

Additional comment

 

We in collaboration with Ehime University have developed a new technology to conduct a genome wide evaluation of the specificity of antibodies that can bind to human proteins.

Category: Press releases Created: Thursday, 19 December 2019

The groups from CellFree Sciences Co., Ltd. (Ryo Morishita, R&D manager)  and  Proteo-Science Center, Ehime University (Professor Tatsuya Sawasaki) have successfully developed a new technology that identifies proteins for binding to target antibodies. Using about 20,000 human proteins this technology is best suited for veriflying the specificity of antibodies against human proteins.

  

The new technology utilizes a protein bead array technology developed by CellFree Sciences Co., Ltd. named “CF-PA2Vtech”. The potential of the new method was demonstrated by verifying the specific binding of a commercial anti-PD-1 antibody, where the data demonstrate its binding to several proteins having related linear epitopes.

 

The results from the research were published by Morishita et al. in the December 18, 2019 issue of Scientific Reports:

 

CF-PA2Vtech: a cell-free human protein array technology for antibody validation against human proteins

https://www.nature.com/articles/s41598-019-55785-5

Copyright © CellFree Sciences Co.,Ltd. All Rights Reserved. [login]

We use cookies to ensure you get the best experience. By using our website you agree to our Cookie Policy.